Taprol

Generic Composition: Pantoprazole sodium

General Introduction

Taprol contains active ingredient Pantoprazole, proton pump inhibitor compounds. More acid stable and less chances of drug interaction.

Therapeutic category

• Proton Pump Inhibitors

Dosage forms available

• TAPROL 40 mg tablets

Mechanism of action

Pantoprazole binds to the sulfhydryl group of H+, K+-ATPase, which is an enzyme implicated in accelerating the final step in the acid secretion pathway. The enzyme is inactivated, inhibiting gastric acid secretion.7 The inhibition of gastric acid secretion is stronger with proton pump inhibitors such as pantoprazole and lasts longer than with the H (2) antagonists. 

Pharmacokinetics

After oral administration, Pantoprazole is well absorbed. It undergoes little first-pass metabolism resulting in an absolute bioavailability of approximately 77%. It has 98% protein binding. It is metabolized in liver and 71% is excreted via urine and 18% is excreted via biliary route. Its half-life is 1 hour.

Uses

• GERD
• Esophagitis
• Eradication of H.pylori in combination with antibiotics
• Zollinger-Ellison Syndrome
• Peptic ulcer
• Heartburn
• Stress ulcer

Dose

40 mg once daily on empty stomach for up to 8 weeks for GERD, esophagitis and 40 mg twice daily for Zollinger-Ellison syndrome.

Side effects

Fever, pain, fatigue, malaise, abdominal swelling, palpitation, elevated blood pressure, peripheral edema, pancreatitis (some fatal), anorexia, irritable colon, flatulence, fecal discoloration, esophageal candidiasis, mucosal atrophy of the tongue, dry mouth, interstitial nephritis (some with positive rechallenge), urinary tract infection, hypochlorhydria.

Contraindication

Pantoprazole is contraindicated in patients with known hypersensitivity to it and the patients undergoing antiretroviral drug therapy

Precautions

• Renally and hepatic impaired patients.
• Pregnant women

Pregnancy category: B

Drug interaction

Risk of drug interaction is minimal.

• Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with pantoprazole may increase toxicity.
• Pantoprazole and Warfarin when taken concomitantly, increases in INR and prothrombin time occurs that may lead to abnormal bleeding and even death.
• Concomitant use of pantoprazole sodium with methotrexate (primarily at high dose) may elevate and prolong serum concentrations of methotrexate and/or its metabolite